Approved Formulary
Add Formweb to your mobile device
Approved Formulary
HIGH ALERT: Please read the COMMENTS very carefully.
Do Not Crush Crushing, chewing, or dissolving slow release tablets can cause rapid release and absorption of a potentially fatal dose
Black Box Warning: Potential for abuse and respiratory depression
Search results for:
HYDROMORPHONE
HYDROMORPHONE
- Drug Administration Guidelines Click here for administration guidelines
- Black Box Warning: Potential for abuse and respiratory depression
| Drug Name | Form | Strength | Non-Formulary | Notes |
|---|---|---|---|---|
| DILAUDID-HP | 10 mg/ml | |||
| HYDROMORPHONE HYDROCHLORIDE | INJECTION | 1 mg/ml | ||
| HYDROMORPHONE HYDROCHLORIDE | INJECTION | 2 mg/ml | ||
| HYDROMORPHONE HYDROCHLORIDE | INJECTION | 4 mg/ml | ||
| DILAUDID- HP | INJECTION | 10 mg/ml | ||
| DILAUDID | SOLUTION | 1 mg/ml | ||
| DILAUDID | SUPPOSITORY | 3 mg | ||
| HYDROMORPHONE HYDROCHLORIDE | TABLET | 2 mg | ||
| HYDROMORPHONE HYDROCHLORIDE | TABLET | 4 mg | ||
| DILAUDID | TABLET | 8 mg | ||
| EXALGO | TABLET, EXTENDED RELEASE |
View Other Therapeutic Options: Opioid Agonists:
280808
High Alert Drug
Last updated: May. 28, 2018
- Do Not Crush Crushing, chewing, or dissolving slow release tablets can cause rapid release and absorption of a potentially fatal dose
Class II
ISMP recommended Tall Man Letters HYDROmorphone to avoid confusion with MORPHine.
The High Risk/High Alert Medication Policy may be found by using the search function in Policies and Procedures.
Double-checks for appropriateness of drug/dose/pump setting/line placement must be performed during PCA/Epidural use.
The High Risk/High Alert Medication Policy may be found by using the search function in Policies and Procedures.